Comparative Antimicrobial Activity of Mul-1867, a Novel Antimicrobial Compound and Amikacin, Against New Clinically Important Airway Pathogens In Cystic Fibrosis: Stenotrophomonas maltophilia, Achromobacterxylosoxidans, Mycobacterium abscessus

ASM Microbe 2016 (June 16–20, 2016, Boston, MA)

Study of Mul-1867, a drug candidate for inhalation therapy of pulmonary exacerbations in patients with cystic fibrosis against innately resistant new airway pathogens such as S.maltophilia, A.xylosoxidans, M.abscessus.